Navigation Links
FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
Date:2/27/2009

ult in chronic airway inflammation(4) and progressive loss of lung function, making it difficult to breathe normally.(4,6)

The FDA approval is based on two pivotal (Phase III) efficacy and safety trials, SHINE and SUN, which evaluated more than 3,600 patients ages 40 years and older with moderate to very severe COPD. (2) These studies demonstrated that patients using SYMBICORT pMDI 160/4.5 mcg had significantly greater mean improvements from baseline in pre-dose forced expiratory volume in one second (FEV1) averaged over the treatment period compared with formoterol 4.5 mcg and placebo.(2)

In addition, patients using SYMBICORT had significantly greater mean improvements from baseline in 1-hour post-dose FEV1 averaged over the treatment period compared with budesonide 160 mcg and placebo.(2) Furthermore, the median time to onset of significant bronchodilation (greater than or equal to 15% improvement in FEV1) was five minutes.(1)

SYMBICORT was generally well-tolerated over the 12-month study,(2) and the incidence of pneumonia was no different for SYMBICORT compared to placebo.(2) There was a higher incidence of potential lung infections other than pneumonia (e.g., bronchitis and viral lower respiratory tract infections) in patients receiving SYMBICORT 160/4.5 mcg than in those receiving formoterol 4.5 mcg or placebo.(2) The most common drug-related adverse events reported were nasopharyngitis (the common cold), oral candidiasis, bronchitis, sinusitis and viral upper respiratory tract infection.(2)

"Through these pivotal studies, SYMBICORT demonstrated rapid and sustained improvements in lung function and was generally well-tolerated long-term for patients with moderate to severe COPD,"(2) said lead investigator Dr. Donald Tashkin of the University of California, Los Angeles (UCLA). "Healthcare professionals and patients with severe COPD can now consider using SYMBI
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
2. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
3. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
4. FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
5. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
6. FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD
7. Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project
8. Monsanto Board Approves 10 Percent Dividend Increase
9. FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C
10. MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
11. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... TRIANGLE PARK, N.C. and ... agricultural research firm AgBiome, and Genective, key developer ... to accelerate the discovery of new generations of ... traits for insect control to counter the realities ... partner with Genective, aligning AgBiome,s unique insect control ...
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
(Date:7/1/2015)... , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite   ... technical and medical information products and services, announced today the ... clinical decision support (CDS) technology company. InferMed,s Arezzo ...
(Date:6/30/2015)... , July 1, 2015 R-Japan Co.,Ltd. obtained the ... Safety of Regenerative Medicine from the Ministry of Health, Labour ... 29, 2015. The fact that R- ... through the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) ... allows it to provide stem cell manufacturing service to medical ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... Fla., Feb. 22, 2011 Seventy-two start ups, 2,500 ... three new ways to measure the progress of Indiana,s ... and important part of the state,s economy.  ... a new report, From Dishwashers to Digital Medical ...
... Qteros, Inc., the developer of a unique and ... the lowest-cost production of cellulosic ethanol, today announced its ... A. McCarthy, Jr., Qteros, President and Chief Executive Officer, ... 11th Global Clean Technology Conference being held at the ...
... Otonomy, Inc., a developer of innovative therapeutics for ... positive results for the company,s lead product candidate, ...  Data demonstrated that a single intratympanic (IT) injection ... the corticosteroid dexamethasone, provided significant protection against both ...
Cached Biology Technology:Advancing Patient Care and Driving Economic Impact, Indiana's Health Information Technology Innovation Cluster Serves as National Model 2Advancing Patient Care and Driving Economic Impact, Indiana's Health Information Technology Innovation Cluster Serves as National Model 3Advancing Patient Care and Driving Economic Impact, Indiana's Health Information Technology Innovation Cluster Serves as National Model 4Qteros Management to Present at Alternative Energy Investment Banking Conferences 2Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 2Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 3
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
(Date:6/15/2015)... 2015 According to a new ... (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern ... by MarketsandMarkets, The Natural Language Processing Market is expected ... 18.4% for the forecast period 2015-2020. ... igures spread   through 155 P ages ...
(Date:6/11/2015)... Daon, a global leader in mobile ... Mobile Authentication Platform v4.0 has been FIDO Certified™.  ... industry consortium launched in 2013 to revolutionize online ... In order to receive certification, a company,s products ... tests that measure compliance and ensure interoperability among ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... Scientists at St. Jude Children,s Research Hospital have found key ... that infect humans. The St. Jude team used ... that are statistically more likely to appear in avian influenza ... in human influenza virus proteins. The differences in these amino ...
... compound which could remove the need for patients to ... been created by scientists at Durham University. Research ... this new compound could be used in a chemically-sensitive ... of diseases such as cancer, without the need for ...
... Scientists at Pacific Northwest National Laboratory,have discovered ... strips that,will enable creation of a portable biosensor ... involving chemical or nerve agents, the need to ... the worried well. The sensor components resemble ...
Cached Biology News:St. Jude influenza survey uncovers key differences between bird flu and human flu 2St. Jude influenza survey uncovers key differences between bird flu and human flu 3New 'chemically-sensitive MRI scan' may bypass some invasive diagnostic tests in next decade 2Truly sick or simply scared? 2
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
... - Conjugation Alkaline Phosphatase ... Conjugation Fluorescein Isothiocyanate Conjugation R. ... Conjugation Alexa Fluor 488 Conjugation ... 405 Conjugation Rpe-Alexa Fluor 750 Conjugation ...
Request Info...
... This Kit Contains the following: , Coated Capture ... sealers , Wash/Sample Diluent: 300 mL of 2X ... vial 10 microg lyophilized peptide , Lyophilized Standard ... of 50X concentrate , Secondary Antibody-HRP: 30 microL ...
Biology Products: